infectious diseases
Chronic Fatigue – Retroviruses to Blame, or Not?
Chronic fatigue syndrome has long been controversial and mysterious. Is the mystery clearing up, or getting deeper?
Novavax shares soar on NIH swine flu agreement
Novavax saw its stock
Altermune – Real Stuff or Not?
Kary Mullis is an outlier among Nobel Prize winners.
Angiogenesis Inhibitors: Helping or Hurting?
Now, here’s something to think about: can angiogenesis inhibitors, the famous class of tumor-starving cancer drugs, actually make some kinds of cancer worse?
Into the Clinic. And Right Back Out.
Here’s a good example of why all of us in the industry tiptoe into Phase I trials, the first-in-man studies. A company called SGX, recently acquired by Eli Lilly, has been developing a kinase inhibitor (SGX523) targeting the enzyme cMET.
Farewell to ACAT, and to Lots of Time and Money, Too
Back when I joined the first drug company I ever worked for, the group in the lab next door was working on an enzyme called ACAT, acyl CoA:cholesterol acyltranferase. It’s the main producer of cholesterol esters in cells, and is especially known to be active in the production of foam cells in atherosclerosis. It had already been a drug target for some years before I first heard about it, and has remained one.
Don’t Hit The Bunkers Just Yet
Swine flu: is it time to panic yet? Actually, it never is, and this is a particularly useless time to start running in circles, despite the apparent non-stop coverage on the cable news channels.










Business Week – Drug Marketing
Business Week – Pharma Marketing
Cafe Pharma
Clinical Trials.gov
FDA on Twitter
Pharma Live
Pharma Voice